These findings suggest that HSP90AB1 forms a complex with IGF1R that causes cisplatin resistance and that inhibition of HSP90 ATPase activity enhances the effect of ME treatment on increasing the sensitivity of chemoresistant ovarian cancer cells to cisplatin. This evidence concerns the gene HSP90AA1 and ovarian carcinoma.